Related Experiment Videos
Unsuccessful DTIC treatment of a patient with glucagonoma syndrome
Acta Medica Scandinavica
|January 1, 1983
Abstract:
Various chemotherapeutic modalities have been tried in the treatment of patients with malignant glucagonomas. Promising results have been reported after drug treatment with dimethyltriazenoimidazole carboxamide (DTIC). We present a patient with a metastasizing pancreatic glucagonoma, in whom treatment with neither DTIC nor with the combination of streptozotocin and 5-fluorouracil resulted in any noticeable improvement.
Insights
Dimethyltriazenoimidazole carboxamide (DTIC) shows promise for malignant glucagonomas. However, one patient with metastatic pancreatic glucagonoma showed no improvement with DTIC or streptozotocin/5-fluorouracil combination therapy.
Area of Science:
- Oncology
- Endocrinology
- Medical Chemistry
Background:
- Malignant glucagonomas are rare neuroendocrine tumors with limited treatment options.
- Chemotherapy is a common approach for managing metastatic disease.
- Dimethyltriazenoimidazole carboxamide (DTIC) has shown some efficacy in prior studies.
Observation:
- This report details a case of a patient diagnosed with a metastasizing pancreatic glucagonoma.
- The patient's tumor exhibited resistance to standard chemotherapeutic agents.
Findings:
- Treatment with dimethyltriazenoimidazole carboxamide (DTIC) did not yield any significant clinical improvement.
- Combination therapy using streptozotocin and 5-fluorouracil also proved ineffective in managing the patient's condition.
Implications:
- This case highlights the potential for therapeutic resistance in malignant glucagonomas.
- Further research is needed to identify more effective treatment strategies for advanced glucagonoma.
- Individualized treatment approaches may be necessary for patients with refractory disease.